A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India
Top Cited Papers
- 23 July 2009
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (4) , 335-344
- https://doi.org/10.1056/nejmoa0807521
Abstract
Typhoid fever remains an important cause of illness and death in the developing world. Uncertainties about the protective effect of Vi polysaccharide vaccine in children under the age of 5 years and about the vaccine's effect under programmatic conditions have inhibited its use in developing countries.This publication has 23 references indexed in Scilit:
- Policymakers’ views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in AsiaVaccine, 2004
- Vaccines against cholera, typhoid fever and shigellosis for developing countriesExpert Opinion on Biological Therapy, 2004
- Comparative Tolerability and Immunogenicity of Typherix??? or Typhim Vi??? in Healthy Adults*BioDrugs, 2001
- Simple sample size calculation for cluster-randomized trialsInternational Journal of Epidemiology, 1999
- Study Designs for Evaluating Different Efficacy and Effectiveness Aspects of VaccinesAmerican Journal of Epidemiology, 1997
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989
- Prevention of Typhoid Fever in Nepal with the VI Capsular Polysaccharide ofSalmonella TyphiNew England Journal of Medicine, 1987
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986
- Influence functions for proportional hazards regressionBiometrika, 1985